Glytec announced today that it entered into a strategic partnership with Nebraska Medicine to advance patient safety and innovation in insulin management.
Under the agreement, Nebraska Medicine will implement Glytec’s eGlycemic Management System (eGMS) across all 800 beds at its two hospitals: the Nebraska Medical Center and Bellevue Medical Center. The agreement also includes collaboration on research and development initiatives to improve the safety and efficacy of insulin management in all hospital departments.
Waltham, Massachusetts-based Glytec designed its eGMS with the FDA-cleared Glucommander algorithm, which uses real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs. The system provides a personalized treatment regime that can reduce hypoglycemia, hyperglycemia, lengths of stay, readmissions and cost of care.
“This partnership brings the resources and talents of two leading organizations together to improve how all caregivers in a hospital manage patient insulin,” Nebraska Medicine Chief Transformation Officer and Vice Chancellor of Information and Technology for the University of Nebraska Medical Center Dr. Michael Ash said in a news release. “We started looking at Glytec to enhance capabilities for our pharmacy team, but it became clear that our entire organization, from doctors and nurses to information technology, would see tremendous benefit. We knew our team would want to push the boundaries of the technology to drive value for our patients and our business to become leaders in glycemic control. Formalizing that drive for innovation through a strategic partnership with Glytec made perfect sense.”
Glytec says its eGMS with Glucommander offers clinicians a guide to achieve the best practice care and workflows through alerts of glycemic disarray, personalized treatment recommendations and safety guardrails.
The partnership aims to foster collaboration on research and pilot programs for improving inpatient insulin management using Glytec’s computer-guided dosing software. Aims of the initiatives undertaken by Glytec and Nebraska Medicine will center around clinical and technical innovation that could include data and analytics, regulatory engagement, workflow development and other areas.
“Nebraska Medicine is known nationally and internationally for its leadership in endocrinology. Implementing our eGMS across its hospitals and dedicating specific resources to share feedback and embark on joint research initiatives will create a powerful environment for pushing the field of glycemic management forward,” Glytec CCO John Downey said. “As leadership at hospitals across the country place a growing focus on their hyperglycemia and hypoglycemia rates as a result of new CMS reporting measures announced this year, our work with Nebraska Medicine will be an important resource to further our study of how clinicians manage blood sugar in the hospital and continuously develop innovative solutions that enhance patient safety.”